Ezetimibe/simvastatin

Bibliography

• Manktelow BN, Potter JF. Interventions in the management of serum lipids for preventing stroke recurrence. Cochrane Database Syst Rev 2009;(3):CD002091
   Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF heart protection study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
   PubMed Web of Science ®Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7
   PubMed Web of Science ®Google Scholar
• Robinson JG, Smith B, Maheshwari N, Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005;46:1855-62
   PubMed Web of Science ®Google Scholar
• Davidson MH. Clinical significance of statin pleiotropic effects: hypotheses versus evidence. Circulation 2005;111:2280-1
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Pfeffer MA, Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-5
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Clearfield M, Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65
   PubMed Web of Science ®Google Scholar
• Shishehbor MH, Brennan ML, Aviles RJ, Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003;108:426-31
   PubMed Web of Science ®Google Scholar
• Laufs U, La Fata V, Plutzky J, Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-35
   PubMed Web of Science ®Google Scholar
• Kleemann R, Princen HM, Emeis JJ, Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 2003;108:1368-74
   PubMed Web of Science ®Google Scholar
• Montecucco F, Mach F. Update on statin-mediated anti-inflammatory activities in atherosclerosis. Semin Immunopathol 2009; DOI 10.1007/s00281-009-0150-y
   Web of Science ®Google Scholar
• Alsheikh-Ali AA, Karas RH. The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials. Curr Atheroscler Rep 2009;11:100-4
   PubMed Web of Science ®Google Scholar
• Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol 2007;49:1753-62
   PubMed Web of Science ®Google Scholar
• Altmann SW, Davis HR Jr, Zhu LJ, Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004;303:1201-4
   PubMed Web of Science ®Google Scholar
• Dembowski E, Davidson MH. Statin and ezetimibe combination therapy in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 2009;16:183-8
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Akdim F, Stroes ES, Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43
   PubMed Web of Science ®Google Scholar
• Rossebø AB, Pedersen TR, Boman K, Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-56
   PubMed Web of Science ®Google Scholar
• Goldberg AC, Sapre A, Liu J, Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004;79:620-9
   PubMed Web of Science ®Google Scholar
• Davidson MH, McGarry T, Bettis R, Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-34
   PubMed Web of Science ®Google Scholar
• Sudhop T, Reber M, Tribble D, Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. J Lipid Res 2009. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Tobert JA. Simvastatin: a review. Expert Opin Pharmacother 2004;5:2583-96
   PubMed Web of Science ®Google Scholar
• Mach F. Toward a role for statins in immunomodulation. Mol Interv 2002;2:478-80
   PubMedGoogle Scholar
• Musial J, Undas A, Gajewski P, Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 2001;77:247-53
   PubMed Web of Science ®Google Scholar
• Hernández-Perera O, Pérez-Sala D, Soria E, Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 2000;87:616-22
   PubMed Web of Science ®Google Scholar
• Henrich D, Seebach C, Wilhelm K, High dosage of simvastatin reduces TNF-alpha-induced apoptosis of endothelial progenitor cells but fails to prevent apoptosis induced by IL-1beta in vitro. J Surg Res 2007;142:13-9
   PubMed Web of Science ®Google Scholar
• Spiel AO, Mayr FB, Leitner JM, Simvastatin and rosuvastatin mobilize Endothelial Progenitor Cells but do not prevent their acute decrease during systemic inflammation. Thromb Res 2008;123:108-13
   PubMed Web of Science ®Google Scholar
• Liang YJ, Shyu KG, Wang BW, Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. Cardiology 2008;110:182-90
   PubMed Web of Science ®Google Scholar
• Eccles KA, Sowden H, Porter KE, Simvastatin alters human endothelial cell adhesion molecule expression and inhibits leukocyte adhesion under flow. Atherosclerosis 2008;200:69-79
   PubMed Web of Science ®Google Scholar
• Chen H, Ren JY, Xing Y, Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: a dose-response effect dependent on endothelial nitric oxide synthase. Int J Cardiol 2009;131:313-20
   PubMed Web of Science ®Google Scholar
• Naoum JJ, Zhang S, Woodside KJ, Aortic eNOS expression and phosphorylation in Apo-E knockout mice: differing effects of rapamycin and simvastatin. Surgery 2004;136:323-8
   PubMed Web of Science ®Google Scholar
• Liu PY, Liu YW, Lin LJ, Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 2009;119:131-8
   PubMed Web of Science ®Google Scholar
• Veillard NR, Braunersreuther V, Arnaud C, Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 2006;188:51-8
   PubMedGoogle Scholar
• Han KH, Ryu J, Hong KH, HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation 2005;111:1439-47
   PubMed Web of Science ®Google Scholar
• Montecucco F, Burger F, Pelli G, Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes. Rheumatology (Oxford) 2009;48:233-42
   PubMed Web of Science ®Google Scholar
• Day AP, Bellavia S, Jones OT, Effect of simvastatin therapy on cell membrane cholesterol content and membrane function as assessed by polymorphonuclear cell NADPH oxidase activity. Ann Clin Biochem 1997;34:269-75
   PubMed Web of Science ®Google Scholar
• Deskur-Smielecka E, Wykretowicz A, Banaszak A, The influence of treatment of hypercholesterolemic patients with simvastatin on plasma chemotactic activity and adherence of neutrophils. Int J Cardiol 2000;75:85-90
   PubMed Web of Science ®Google Scholar
• Rudich SM, Mongini PK, Perez RV, HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation. Transplant Proc 1998;30:992-5
   PubMed Web of Science ®Google Scholar
• Ghittoni R, Patrussi L, Pirozzi K, Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J 2005;19:605-7
   PubMed Web of Science ®Google Scholar
• Evans J, Powell JT, Schwalbe E, Simvastatin attenuates the activity of matrix metalloprotease-9 in aneurysmal aortic tissue. Eur J Vasc Endovasc Surg 2007;34:302-3
   PubMed Web of Science ®Google Scholar
• Ferri N, Colombo G, Ferrandi C, Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation. Arterioscler Thromb Vasc Biol 2007;27:1043-9
   PubMed Web of Science ®Google Scholar
• Huang CY, Wu TC, Lin WT, Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients. Eur J Clin Invest 2006;36:76-84
   PubMed Web of Science ®Google Scholar
• Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003;23:769-75
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Marx N, Pfützner A, Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 2007;49:290-7
   PubMed Web of Science ®Google Scholar
• Arnaud C, Burger F, Steffens S, Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol 2005;25:1231-6
   PubMed Web of Science ®Google Scholar
• Pearson T, Ballantyne C, Sisk C, Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol 2007;99:1706-13
   PubMed Web of Science ®Google Scholar
• van Heek M, Farley C, Compton DS, Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001;134:409-17
   PubMed Web of Science ®Google Scholar
• Salen G, von Bergmann K, Lütjohann D, Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 2004;109:966-71
   PubMed Web of Science ®Google Scholar
• van Heek M, Farley C, Compton DS, Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000;129:1748-54
   PubMed Web of Science ®Google Scholar
• Patrick JE, Kosoglou T, Stauber KL, Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos 2002;30:430-7
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Johnson-Levonas AO, Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005;44:467-94
   PubMed Web of Science ®Google Scholar
• Davis HR Jr, Pula KK, Alton KB, The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Metabolism 2001;50:1234-41
   PubMed Web of Science ®Google Scholar
• Mäki-Petäjä KM, Booth AD, Hall FC, Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007;50:852-8
   PubMed Web of Science ®Google Scholar
• Pearson TA, Ballantyne CM, Veltri E, Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol 2009;103:369-74
   PubMed Web of Science ®Google Scholar
• Kuhlencordt PJ, Padmapriya P, Rützel S, Ezetimibe potently reduces vascular inflammation and arteriosclerosis in eNOS-deficient ApoE ko mice. Atherosclerosis 2009;202:48-57
   PubMed Web of Science ®Google Scholar
• Gomez-Garre D, Munoz-Pacheco P, Gonzalez-Rubio M, Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect. Br J Pharmacol 2009; doi:10.1111/j.1476-5381.2008.00091.x
   PubMed Web of Science ®Google Scholar
• Capps N. Total and low-density lipoprotein cholesterol responses to ezetimibe in clinical practice. Int J Clin Pract 2006;60:867-9
   PubMed Web of Science ®Google Scholar
• Kalogirou M, Tsimihodimos V, Gazi I, Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 2007;23:1169-76
   PubMed Web of Science ®Google Scholar
• Ose L, Reyes R, Johnson-Levonas AO, Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Clin Ther 2007;29:2419-32
   PubMed Web of Science ®Google Scholar
• Nakou ES, Filippatos TD, Kiortsis DN, The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin Pharmacother 2008;9:3151-8
   PubMed Web of Science ®Google Scholar
• Tribble DL, Farnier M, Macdonell G, Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metabolism 2008;57:796-801
   PubMed Web of Science ®Google Scholar
• Tomassini JE, Mazzone T, Goldberg RB, Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia. Diabetes Obes Metab 2009; doi:10.1111/j.1463-1326.2009.01061.x
   PubMed Web of Science ®Google Scholar
• Pearson TA, Denke MA, McBride PE, A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005;80:587-95
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Abate N, Yuan Z, Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005;149:464-73
   PubMed Web of Science ®Google Scholar
• Davidson MH, McGarry T, Bettis R, Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-34
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Guyton JR, Mazzone T, Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc 2006;81:1579-88
   PubMed Web of Science ®Google Scholar
• Farnier M, Averna M, Missault L, Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. Int J Clin Pract 2009;63:547-59
   PubMed Web of Science ®Google Scholar
• Stein EA. Additional lipid lowering trials using surrogate measurements of atherosclerosis by carotid intima-media thickness: more clarity or confusion? J Am Coll Cardiol 2008;52:2206-9
   PubMed Web of Science ®Google Scholar
• Fleg JL, Mete M, Howard BV, Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008;52:2198-205
   PubMed Web of Science ®Google Scholar
• Meaney A, Ceballos G, Asbun J, The Vytorin on Carotid Intima-Media Thickness and Overall Arterial Rigidity (VYCTOR) Study. J Clin Pharmacol 2009;49:838-47
   PubMed Web of Science ®Google Scholar
• Sugrue DD, Trayner I, Thompson GR, Coronary artery disease and haemostatic variables in heterozygous familial hypercholesterolaemia. Br Heart J 1985;53:265-8
   PubMedGoogle Scholar
• Reckless JP, Henry P, Pomykaj T, Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int J Clin Pract 2008;62:539-54
   PubMed Web of Science ®Google Scholar
• Chenot F, Montant PF, Marcovitch O, Co-administration of ezetimibe and simvastatin in acute myocardial infarction. Eur J Clin Invest 2007;37:357-63
   PubMed Web of Science ®Google Scholar
• Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int 2003;63(Suppl 84):S207-10
   Google Scholar
• Cannon CP, Giugliano RP, Blazing MA, Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008;156:826-32
   PubMed Web of Science ®Google Scholar
• Gerdts E, Rossebo AB, Pedersen TR, Impact of severity of aortic valve stenosis on effect of intensive lipid lowering therapy. Insights from the SEAS study. J Am Coll Cardiol 2009;53(10 Suppl A):A415
   Google Scholar
• Mäki-Petäjä KM, Booth AD, Hall FC, Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007;50:852-8
   PubMed Web of Science ®Google Scholar
• Shirinsky IV, Zheltova OI, Solovyova NY, Changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment. Scand J Rheumatol 2009;38:23-7
   PubMed Web of Science ®Google Scholar
• Hermann F, Forster A, Chenevard R, Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol 2005;45:461-4
   PubMed Web of Science ®Google Scholar
• Westerweel PE, Visseren FL, Hajer GR, Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy. Eur Heart J 2008;29:2808-17
   PubMed Web of Science ®Google Scholar
• Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. Atherosclerosis 2009;202:216-24
   PubMed Web of Science ®Google Scholar
• Olijhoek JK, Hajer GR, van der Graaf Y, The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial. J Cardiovasc Pharmacol 2008;52:145-50
   PubMed Web of Science ®Google Scholar
• Kashani A, Phillips CO, Foody JM, Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006;114:2788-97
   PubMed Web of Science ®Google Scholar
• Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97:52C-60C
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study Collaborative Group. Effects of simvastatin 40mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people. BMC Clin Pharmacol 2009;9:6
   PubMedGoogle Scholar
• Pasanen MK, Neuvonen M, Neuvonen PJ, SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006;16:873-9
   PubMed Web of Science ®Google Scholar
• Bradford PG, Awad AB. Phytosterols as anticancer compounds. Mol Nutr Food Res 2007;51:161-70
   PubMed Web of Science ®Google Scholar
• Mascitelli L, Ravnskov U, Pezzetta F, After the failure of ENHANCEd cholesterol lowering in familial hypercholesterolemia, SEAS of problems with ezetimibe. Angiology 2009;60:127-8
   PubMed Web of Science ®Google Scholar
• Peto R, Emberson J, Landray M, Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008;359:1357-66
   PubMed Web of Science ®Google Scholar
• Pandor A, Ara RM, Tumur I, Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med 2009;265:568-80
   PubMed Web of Science ®Google Scholar
• Friedman GD, Flick ED, Udaltsova N, Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008;17:27-36
   PubMed Web of Science ®Google Scholar
• Halleck M, Davis HR, Kirschmeier P, An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach. Toxicology 2009;258:116-30
   PubMed Web of Science ®Google Scholar
• Solomon KR, Pelton K, Boucher K, Ezetimibe is an inhibitor of tumor angiogenesis. Am J Pathol 2009;174:1017-26
   PubMed Web of Science ®Google Scholar
• Strony J, Yang B, Hanson ME, Long-term safety and tolerability of ezetimibe coadministered with simvastatin in hypercholesterolemic patients: a randomized, 12-month double-blind extension study. Curr Med Res Opin 2008;24:3149-57
   PubMed Web of Science ®Google Scholar
• van der Graaf A, Cuffie-Jackson C, Vissers MN, Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2008;52:1421-9
   PubMed Web of Science ®Google Scholar
• Strony J, Hoffman R, Hanson M, Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients. Clin Ther 2008;30:2280-97
   PubMed Web of Science ®Google Scholar
• Knopp RH, Gitter H, Truitt T, Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729-41
   PubMed Web of Science ®Google Scholar
• Dujovne CA, Ettinger MP, McNeer JF, Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092-7
   PubMed Web of Science ®Google Scholar
• Davidson MH, Maccubbin D, Stepanavage M, Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol 2006;97:223-8
   PubMed Web of Science ®Google Scholar
• Matsuzawa Y, Kita T, Mabuchi H, Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatement with minimum side effects in 51,321 Japanese hypercholesterolemic patients. Circ J 2003;67:287-94
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD, Early intesive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16
   PubMed Web of Science ®Google Scholar
• Sirtori CR. Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors. Pharmacol Res 1990;22:555-63
   PubMed Web of Science ®Google Scholar
• Alsheikh-Ali AA, Karas RH. Adverse events with concomitant amiodarone and statin therapy. Prev Cardiol 2005;8:95-7
   PubMedGoogle Scholar
• Lipka L, Sager P, Strony J, Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs Aging 2004;21:1025-32
   PubMed Web of Science ®Google Scholar
• Alsheikh-Ali AA, Karas RH. Ezetimibe, and the combination of ezetimibe/simvastatin, and risk of cancer: a post-marketing analysis. J Clin Lipidol 2009;3:138-42
   PubMed Web of Science ®Google Scholar